Search
tepotinib (Tepmetko)
Indications:
- metastatic non-small cell lung cancer harboring MET exon-14 skipping alterations
Dosage:
- 450 mg orally once daily with food
225 MG Oral Tablet
Adverse effects:
- most common (> 20%
- edema, fatigue, nausea, diarrhea, musculoskeletal pain, dyspnea
- less common (> 2%)
- lymphopenia, hypoalbuminemia, hyponatremia, increased gamma-glutamyltransferase, increased amylase, elevated serum transaminases, anemia
- serious:
- interstitial lung disease, hepatotoxicity, embryo-fetal toxicity
Mechanism of action:
- kinase inhibitor that targets met-proto-oncogene protein
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM correlations
References
- RxNorm
- FDA Approval, DFeb 3, 2021
FDA grants accelerated approval to tepotinib for metastatic
non-small cell lung cancer.
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer
- HIGHLIGHTS OF PRESCRIBING INFORMATION
TEPMETKO (tepotinib) tablets, for oral use
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf